Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023 Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company's operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter.

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and thank you for standing by.

Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 --

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial.

Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

Borqs Technologies

Vizsla Silver Corp

The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.

3 Penny Stocks With Surprisingly Superior Fundamentals

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Calithera Biosciences, Inc. (NASDAQ:CALA ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Operator Good day, and welcome to the Calithera Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's second quarter 2022 financial results will be released on Monday, August 15, 2022. Company management will host a conference call on Monday, August 15, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with  relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer --

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in patients with relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC).

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split, effective as of 5:00 p.m. Eastern Time today. The reverse stock split was effected by Calithera in accordance with the authorization, and within the split ratio range, adopted by Calithera stockholders at the 2022 Annual Meeting of Stockholders held on June 1, 2022.

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.

Calithera to Present at the H.C. Wainwright Global Investment Conference

Calithera Biosciences, Inc. (NASDAQ:CALA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Molineaux - Founder, President & CEO Stephanie Wong - CFO Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Nick Abbott - Wells Fargo Ramakanth Swayampakula - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Ladies and gentlemen, thank you for standing by and welcome to Calithera Biosciences 1Q 2022 Earnings.

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call Transcript

-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's first quarter 2022 financial results will be released on Tuesday, May 10, 2022. Company management will host a conference call on Tuesday, May 10, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Farmmi

VEON

Are these under $1 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $1 Now?

Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May

Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript

Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Calithera Biosciences Inc (NASDAQ: CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of common stock is accompanied by a warrant to purchase one common share at an exercise.

News for Calithera Biosciences Stock (CALA)